Introduction to Priligy

In the vast world of pharmaceuticals, a drug- Priligy, also known scientifically as Dapoxetine, is treated as a reliable solution to the evident issue of premature ejaculation in men. Manufactured internationally by various recognized pharmaceuticals, its consumption has gained momentum over the past few years. However, its existence in the pharmaceutical markets of India, its accessibility, and affordability is a subject that needs attention.

The Presence of Priligy in India

Priligy or Dapoxetine has been noted to be available in India. Multiple pharmaceutical companies are manufacturing and distributing the drug, ensuring its ready availability for the Indian consumer base. Concerns were previously arising about the country’s conservative nature towards such issues and their solutions, but it’s commendable to note that the society’s direct needs were prioritized over any prevalent taboos.

Number of Pills Average Cost (In INR)
30 1500 – 2000
60 2500 – 3000
90 3500 – 4000

Owning to the Affordability

Priligy is relatively affordable in India as compared to its prices in international markets. The reasons may be tentatively associated with the large consumer base and competition among the active pharmaceutical companies. Yet, with the average Indian income in mind, it’s agreeable that the prices could climb down a steep further.

Legal Status and Discussions Around Priligy

Despite all the hushed tones, Priligy is a legally accepted pharmaceutical in Indian medical jurisprudence. Health professionals do suggest its consumption, provided its compatibility with the individual’s health is thoroughly examined. The discussions around the medication need to be risen beyond whispers to achieve a more broadened awareness about the solution to premature ejaculation.

Wrap Up: The Widespread Need for Priligy

No pharmaceutical gains popularity unless the need is widespread, and Priligy is no stranger to this fact. The necessity was recognized, and an accessible solution was rendered- this impliedly mirrors the growth of the progressive Indian pharmaceutical market. The current focus should be on ensuring its safety, encouraging conversations about its availability, and stepping towards an India where health is prioritized, across all dimensions.